David A. Ehrmann to Insulin Resistance
This is a "connection" page, showing publications David A. Ehrmann has written about Insulin Resistance.
Connection Strength
3.837
-
Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril. 2022 05; 117(5):897-911.
Score: 0.706
-
Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Oct; 93(10):3878-84.
Score: 0.272
-
Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004 Aug; 287(2):E241-6.
Score: 0.197
-
Weight loss and ß-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial. Obesity (Silver Spring). 2022 08; 30(8):1579-1588.
Score: 0.180
-
Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab. 2002 Feb; 87(2):772-5.
Score: 0.173
-
Insulin resistance and polycystic ovary syndrome. Curr Diab Rep. 2002 Feb; 2(1):71-6.
Score: 0.173
-
Effect of Medical and Surgical Interventions on a-Cell Function in Dysglycemic Youth and Adults in the RISE Study. Diabetes Care. 2021 09; 44(9):1948-1960.
Score: 0.166
-
Hyperglucagonemia Does Not Explain the ß-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care. 2021 09; 44(9):1961-1969.
Score: 0.166
-
Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2021 09; 44(9):1938-1947.
Score: 0.166
-
Liver Fat Reduction After Gastric Banding and Associations with Changes in Insulin Sensitivity and ß-Cell Function. Obesity (Silver Spring). 2021 07; 29(7):1155-1163.
Score: 0.165
-
Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. Pediatr Diabetes. 2020 12; 21(8):1437-1446.
Score: 0.158
-
Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017 09; 60(9):1656-1661.
Score: 0.127
-
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul; 82(7):2108-16.
Score: 0.126
-
The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 10; 37(5):467-520.
Score: 0.118
-
Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016 Feb; 65(2):520-6.
Score: 0.112
-
Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul; 96(1):520-7.
Score: 0.110
-
Impaired insulin signaling in human adipocytes after experimental sleep restriction: a randomized, crossover study. Ann Intern Med. 2012 Oct 16; 157(8):549-57.
Score: 0.091
-
Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Feb; 96(2):365-74.
Score: 0.080
-
Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):215-22.
Score: 0.066
-
Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):36-42.
Score: 0.056
-
Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24; 352(12):1223-36.
Score: 0.054
-
Association of the (AU)AT-rich element polymorphism in PPP1R3 with hormonal and metabolic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 Jun; 89(6):2973-6.
Score: 0.051
-
Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab. 2003 Nov; 88(11):5137-44.
Score: 0.049
-
Pharmacologic treatment of polycystic ovary syndrome. Semin Reprod Med. 2003 Aug; 21(3):277-83.
Score: 0.048
-
Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000 Aug; 106(3):329-33.
Score: 0.039
-
Glucose intolerance in the polycystic ovary syndrome: role of the pancreatic beta-cell. J Pediatr Endocrinol Metab. 2000; 13 Suppl 5:1299-301.
Score: 0.038
-
Association of Habitual Daily Physical Activity With Glucose Tolerance and ß-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2019 08; 42(8):1521-1529.
Score: 0.036
-
Review of methods for measuring ß-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium. Diabetes Obes Metab. 2018 01; 20(1):14-24.
Score: 0.031
-
Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus. Baillieres Clin Obstet Gynaecol. 1997 Jun; 11(2):335-47.
Score: 0.031
-
Interactions between pregnancy, obstructive sleep apnea, and gestational diabetes mellitus. J Clin Endocrinol Metab. 2013 Oct; 98(10):4195-202.
Score: 0.024
-
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr; 54(4):1150-6.
Score: 0.013
-
Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003 Apr; 79(4):932-7.
Score: 0.012